LB Pharmaceuticals specializes in developing LB-102 (n-Methyl amisulpride) as a treatment for schizophrenia.
LB Pharmaceuticals has raised $150.0M in total funding. The most recent round was Post-IPO Equity. The last funding was announced in July 2026.
LB Pharmaceuticals's investors include Balyasny Asset Management, TCG Crossover, Commodore Capital, Adage Capital Management, Pivotal bioVenture Partners.
LB Pharmaceuticals is headquartered in New York, United States.
LB Pharmaceuticals specializes in developing LB-102 (n-Methyl amisulpride) as a treatment for schizophrenia.
LB Pharmaceuticals is at the Post-IPO Equity stage.
Free to use in articles, research, and reference works. Stable URL — will not change. Data on this page last updated .
"LB Pharmaceuticals — Funding & Investors." VCBacked, July 29, 2026, https://www.vcbacked.co/company/lb-pharmaceuticals. Accessed November 13, 2026.
VCBacked. (2026). LB Pharmaceuticals — Funding & Investors. Retrieved November 13, 2026, from https://www.vcbacked.co/company/lb-pharmaceuticals
{{cite web |title=LB Pharmaceuticals — Funding & Investors |url=https://www.vcbacked.co/company/lb-pharmaceuticals |website=VCBacked |access-date=November 13, 2026}}Profile data sourced and verified per the VCbacked methodology · Last funding round dated
Work at LB Pharmaceuticals? Request a listing update